"The high cost of GLP-1 medications, combined with the lack of adequate coverage by insurance plans, has helped fuel a booming online market for cheaper alternatives."
"Many of the GLP-1 drugs advertised on the internet are not the FDA-approved medications but rather 'compounded' GLP-1 products made in compounding pharmacies."
"These brand-name medications have undergone rigorous clinical trials and extensive FDA evaluation, including review of clinical data, manufacturing processes, and facility inspections, to ensure safety, quality and effectiveness."
"Advertisements for weight-loss medications can be appealing, intrusive, confusing, or even misleading, and have sparked widespread concerns about inappropriate use and adverse events."
The demand for GLP-1 medications like Ozempic and Wegovy has surged since 2022, driven by advertisements such as Serena Williams's Super Bowl commercial. These ads reflect a growing interest in weight-loss drugs, but they also raise concerns about misleading information and the risks of unregulated alternatives. Many online options are compounded versions of FDA-approved drugs, which may not have undergone the same rigorous safety evaluations. The high cost and limited insurance coverage for approved medications contribute to the popularity of these alternatives.
Read at Fast Company
Unable to calculate read time
Collection
[
|
...
]